Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
. Triumvira’s T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza’s Cocoon® platform at the C3i Center Inc (C3i) in Montreal Transitioning to Lonza’s Cocoon® Platform enabled Triumvira to escalate development efforts and achieve IND approval in Mehr




